Sign in
Taking peoplePhase 4

Daptomycin vs. Vancomycin for the Treatment of Methicillin Resistant S. Aureus Bacteremia

Key facts

Who runs it
Todd C. Lee MD MPH FIDSA
Where
Australia, Canada, and New Zealand20 sites in 3 countriesChoose a country to see its sites
Trial code
Status
Recruiting
Phase
Phase 4
People taking part
300 people, planned
Started
14 Nov 2024
Expected to end
Nov 2029
Type of study
Interventional, 2 groupsOne group gets an existing treatment, for comparison.
Treatments tested
  • Daptomycin for Injection
  • Vancomycin (IV)
Record updated
9 September 2026

Who can take part

Age
18 years and older
Sex
Women and men
Healthy volunteers
Cannot take part

The registry criteria, word for word

Show all 5 criteriaShow less

Who can take part

  • Methicillin-resistant S. aureus bacteremia

Who cannot take part

  • Severe allergy or non-severe rash to vancomycin or daptomycin
  • Suspected or confirmed MRSA pneumonia
  • Known vancomycin minimum inhibitory concentration (MIC) greater than or equal to 2mg/L or daptomycin MIC greater than or equal to 1mg/L

Other criteria

  • The participant must meet all inclusion and exclusion criteria for the SNAP Platform (NCT05137119) and also the following inclusion and exclusion criteria:

This trial has no sites in United States.

It has sites in 3 countries. Choose a country to see its sites.

About the trial

What the trial wants to find out

This is an open label randomized controlled trial for patients with methicillin resistant S. aureus (MRSA) bloodstream infection which will directly compare the two most commonly used therapies, vancomycin and daptomycin.

Read full original descriptionShow less

This study is an approved sub-study of The Staphylococcus aureus Network Adaptive Platform (SNAP) trial (NCT05137119)

The 2 groups in the trial

  • DaptomycinTreatment being tested

    Daptomycin given by injection at a dose determined by the treating clinicians but no less than 6mg/kg

    Treatment: Daptomycin for Injection

  • VancomycinExisting treatment, for comparison

    Vancomycin given by injection at a dose determined by the treating clinicians to achieve a trough-based or AUC-based target

    Treatment: Vancomycin (IV)

Questions to ask the study team

  1. How often do I need to come in, and for how long each time?
  2. Are travel costs paid?
  3. Can I keep my own doctor?
  4. What happens if I want to stop?

Contact the study team: see the registry record → Contacts and Locations

Print a page for my doctor

Data and sources

Registry record
Listed on ClinicalTrials.gov.How to verify a trial in the registry
Official title
DAPTO-SNAP: Daptomycin vs. Vancomycin for the Treatment of Methicillin Resistant S. Aureus Bacteremia
Record updated
9 September 2026